IRLAB Therapeutics AB (publ) (IRLAB-A) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.097x

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has a cash flow conversion efficiency ratio of 0.097x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr5.26 Million ≈ $565.84K USD) by net assets (Skr54.21 Million ≈ $5.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

IRLAB Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how IRLAB Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read IRLAB Therapeutics AB (publ) total liabilities for a breakdown of total debt and financial obligations.

IRLAB Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Pearl Gold AG F:02P	N/A
Hindcon Chemicals Limited NSE:HINDCON	0.048x
Bionano Genomics Inc NASDAQ:BNGO	-0.094x
Emova Group SA PA:ALEMV	0.190x
Maxeon Solar Technologies Ltd NASDAQ:MAXN	0.148x
Skin Elements Ltd AU:SKN	-0.699x
Pan Malaysia Corporation Bhd KLSE:4081	0.004x
Platinex Inc F:9PX	-0.038x

Annual Cash Flow Conversion Efficiency for IRLAB Therapeutics AB (publ) (2014–2024)

The table below shows the annual cash flow conversion efficiency of IRLAB Therapeutics AB (publ) from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see IRLAB-A company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr32.63 Million ≈ $3.51 Million	Skr-65.59 Million ≈ $-7.06 Million	-2.010x	-41.14%
2023-12-31	Skr115.76 Million ≈ $12.46 Million	Skr-164.85 Million ≈ $-17.74 Million	-1.424x	-190.40%
2022-12-31	Skr290.83 Million ≈ $31.30 Million	Skr-142.61 Million ≈ $-15.35 Million	-0.490x	-252.28%
2021-12-31	Skr399.48 Million ≈ $42.99 Million	Skr128.64 Million ≈ $13.84 Million	0.322x	+225.57%
2020-12-31	Skr347.88 Million ≈ $37.44 Million	Skr-89.21 Million ≈ $-9.60 Million	-0.256x	+48.87%
2019-12-31	Skr181.83 Million ≈ $19.57 Million	Skr-91.20 Million ≈ $-9.81 Million	-0.502x	-50.55%
2018-12-31	Skr212.48 Million ≈ $22.87 Million	Skr-70.79 Million ≈ $-7.62 Million	-0.333x	+10.56%
2017-12-31	Skr155.00 Million ≈ $16.68 Million	Skr-57.74 Million ≈ $-6.21 Million	-0.373x	+5.19%
2016-12-31	Skr103.89 Million ≈ $11.18 Million	Skr-40.82 Million ≈ $-4.39 Million	-0.393x	-30.74%
2015-12-31	Skr92.03 Million ≈ $9.90 Million	Skr-27.66 Million ≈ $-2.98 Million	-0.301x	-141.45%
2014-12-31	Skr88.57 Million ≈ $9.53 Million	Skr-11.02 Million ≈ $-1.19 Million	-0.124x	--

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$12.86 Million

Skr119.48 Million SEK

Market Cap Rank

#26241 Global

#563 in Sweden

Share Price

Skr1.41

Change (1 day)

-0.85%

52-Week Range

Skr1.41 - Skr7.58

All Time High

Skr104.95